TapImmune To Present at 2018 Janney Healthcare Conference

JACKSONVILLE, Florida – September 12, 2018 – TapImmune Inc . (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will present at the 2018 Janney Montgomery Scott Healthcare Conference being held September 17-18, 2018, at the Union League Club in New York City. He will also be available…

Details

TapImmune to Participate at Two Upcoming Industry Conferences

JACKSONVILLE, Florida – August 29, 2018 – TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will participate at two upcoming industry conferences.  Mr. Hoang will present and participate in a panel discussion at the Hanson Wade CAR-TCR Summit , to be held September 4-7, 2018,…

Details

FISION and Continuity Logic Announce Entry into Merger Agreement, Creating a First of its Kind Cloud Platform for Critical Business Processes, from Digital Asset Management and Agile Marketing, to Business Continuity and Risk Management

FISION and Continuity Logic Announce Entry into Merger Agreement, Creating a First of its Kind Cloud Platform for Critical Business Processes, from Digital Asset Management and Agile Marketing, to Business Continuity and Risk Management Read: FISION and Continuity Logic Announce Entry into Merger Agreement, Creating a First of its Kind Cloud Platform for Critical Business…

Details

TapImmune Announces Pricing of $70 Million Private Placement

Financing Led by New Enterprise Associates (NEA) Financing to Close Concurrently with Close of Merger with Marker Therapeutics JACKSONVILLE, Florida, June 8, 2018 – TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of…

Details